These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

781 related items for PubMed ID: 3894520

  • 1. Studies on macrophage-activating factor (MAF) in antitumor immune responses. I. Tumor-specific Lyt-1+2- T cells are required for producing MAF able to generate cytolytic as well as cytostatic macrophages.
    Nakajima H, Fujiwara H, Takai Y, Izumi Y, Sano S, Tsuchida T, Hamaoka T.
    J Immunol; 1985 Sep; 135(3):2199-205. PubMed ID: 3894520
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Requirements of adherent cells for activating Lyt-1+2- T cells as well as for functioning as antitumor effectors activated by factor(s) from Lyt-1+2- T cells.
    Sakamoto K, Fujiwara H, Nakajima H, Yoshioka T, Takai Y, Hamaoka T.
    Jpn J Cancer Res; 1986 Nov; 77(11):1142-52. PubMed ID: 3098724
    [Abstract] [Full Text] [Related]

  • 4. Studies on macrophage-activating factor (MAF) in antitumor immune responses. II. Molecular characterization of MAF produced by the tumor-immune Lyt-1+2- T cell subset.
    Nakajima H, Izumi Y, Sugihara S, Satoh Y, Isumi S, Gotoh T, Fujiwara H, Hamaoka T.
    Cancer Immunol Immunother; 1987 Nov; 25(3):201-8. PubMed ID: 3119213
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. The role of tumor-specific Lyt-1+2- T cells in eradicating tumor cells in vivo. I. Lyt-1+2- T cells do not necessarily require recruitment of host's cytotoxic T cell precursors for implementation of in vivo immunity.
    Fujiwara H, Fukuzawa M, Yoshioka T, Nakajima H, Hamaoka T.
    J Immunol; 1984 Sep; 133(3):1671-6. PubMed ID: 6205091
    [Abstract] [Full Text] [Related]

  • 7. Macrophage tumoricidal activity as a possible antitumor mechanism associated with the local injection of allogeneic spleen cells into rats.
    Kawase I, Komuta K, Namba M, Yokota S, Ogura T, Kishimoto S.
    Cancer Res; 1986 Mar; 46(3):1047-54. PubMed ID: 3510719
    [Abstract] [Full Text] [Related]

  • 8. Augmentation of antitumor immune response by trinitrophenyl (TNP)-reactive helper T-cells: enhanced induction of tumor-specific Lyt-1+2- T-cell-mediated delayed-type hypersensitivity from spleen cells of tumor-bearing mice by TNP helpers.
    Suda T, Fujiwara H, Mizushima Y, Shearer GM, Hamaoka T.
    J Natl Cancer Inst; 1986 Dec; 77(6):1267-72. PubMed ID: 2948049
    [Abstract] [Full Text] [Related]

  • 9. The role of anti-asialo GM1 antibody-sensitive cells in the implementation of tumor-specific T cell-mediated immunity in vivo.
    Yoshioka T, Sato S, Fujiwara H, Hamaoka T.
    Jpn J Cancer Res; 1986 Aug; 77(8):825-32. PubMed ID: 3093429
    [Abstract] [Full Text] [Related]

  • 10. Rejection of syngeneic tumor cells by the interaction of Lyt-1+ T lymphocytes and macrophages.
    Mitani M, Matsumoto T, Mori K, Miake S, Himeno K, Nomoto K.
    J Clin Lab Immunol; 1985 Oct; 18(2):97-101. PubMed ID: 3935795
    [Abstract] [Full Text] [Related]

  • 11. Helper T cells against tumor-associated antigens (TAA): preferential induction of helper T cell activities involved in anti-TAA cytotoxic T lymphocyte and antibody responses.
    Fujiwara H, Yoshioka T, Shima J, Kosugi A, Itoh K, Hamaoka T.
    J Immunol; 1986 Apr 01; 136(7):2715-9. PubMed ID: 3005417
    [Abstract] [Full Text] [Related]

  • 12. Interleukin 2 enhancement of lymphokine secretion by T lymphocytes: analysis of established clones and primary limiting dilution microcultures.
    Kelso A, MacDonald HR, Smith KA, Cerottini JC, Brunner KT.
    J Immunol; 1984 Jun 01; 132(6):2932-8. PubMed ID: 6233365
    [Abstract] [Full Text] [Related]

  • 13. A dissociated induction of MCF-producing and MAF-producing T cells specific for Listeria monocytogenes in the in vitro primary culture system.
    Muramori K, Mitsuyama M, Handa T, Serushago BA, Nomoto K.
    Immunology; 1991 Mar 01; 72(3):373-9. PubMed ID: 1902819
    [Abstract] [Full Text] [Related]

  • 14. Production of macrophage-activating factor by T lymphocyte clones and correlation with other lymphokine activities.
    Kelso A, Glasebrook AL, Kanagawa O, Brunner KT.
    J Immunol; 1982 Aug 01; 129(2):550-6. PubMed ID: 7045227
    [Abstract] [Full Text] [Related]

  • 15. Lymphocyte-induced macrophage cytotoxicity. Production of specific macrophage arming factor by sensitized Lyt 1+2+ T-lymphocytes.
    Pels E, De Weger RA, Den Otter W.
    Int Arch Allergy Appl Immunol; 1984 Aug 01; 74(2):140-6. PubMed ID: 6609130
    [Abstract] [Full Text] [Related]

  • 16. Interferon-induced enhancement of macrophage-mediated tumor cytolysis and its difference from activation by lymphokines.
    Boraschi D, Tagliabue A.
    Eur J Immunol; 1981 Feb 01; 11(2):110-4. PubMed ID: 6163639
    [Abstract] [Full Text] [Related]

  • 17. Cell-mediated immune responses to syngeneic tumors. I. Identification of two distinct CTL effector pathways which differ in antigen specificity, genetic regulation, and cell surface phenotype.
    Lynch DH, Daynes RA, Hodes RJ.
    J Immunol; 1986 Feb 15; 136(4):1521-7. PubMed ID: 2418117
    [Abstract] [Full Text] [Related]

  • 18. Macrophage activation by interferon-gamma from host-protective T cells is inhibited by interleukin (IL)3 and IL4 produced by disease-promoting T cells in leishmaniasis.
    Liew FY, Millott S, Li Y, Lelchuk R, Chan WL, Ziltener H.
    Eur J Immunol; 1989 Jul 15; 19(7):1227-32. PubMed ID: 2503386
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Evidence for cytostatic T cell activity in the effector mechanism against syngeneic TMT mammary tumor cells in mice.
    Kurata S, Tsuchiya T, Norimura T, Yamashita U.
    J Immunol; 1983 Jan 15; 130(1):496-500. PubMed ID: 6600195
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 40.